trending Market Intelligence /marketintelligence/en/news-insights/trending/GfoxMDJr2WLLtLs130FByQ2 content esgSubNav
In This List

Biogen secures US FDA approval for spinal muscular atrophy treatment

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Biogen secures US FDA approval for spinal muscular atrophy treatment

Biogen Inc. said it received U.S. FDA approval for SPINRAZA, a treatment for spinal muscular atrophy.

The drug was approved following positive results from multiple clinical studies in more than 170 patients. In a controlled clinical study, those treated with the drug showed clinically meaningful improvements in their motor functions. Also, a greater percentage of patients on the drug survived compared to untreated patients.

Biogen plans to make the drug available for shipment in the U.S. to healthcare providers in about a week.